監管
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
Agilent received FDA approval for its PD-L1 IHC 28-8 pharmDx diagnostic test covering esophageal and gastric cancers.
大盤 開啟原文 ↗